Recro Pharma Inc (REPH) - NASDAQ
  • Tue, Jul. 5, 4:46 PM
    • Recro Pharma (NASDAQ:REPH) appoints Michael Celano as Chief Financial Officer effective immediately. Previously, he was Principal and Founder of Lafayette Hill Consulting.
    | Tue, Jul. 5, 4:46 PM
  • Thu, May 12, 9:12 AM
    • Recro Pharma (NASDAQ:REPH): Q1 EPS of -$0.71 misses by $0.05.
    • Revenue of $17.74M beats by $4.74M.
    • Press Release
    | Thu, May 12, 9:12 AM
  • Tue, Apr. 5, 12:45 PM
    | Tue, Apr. 5, 12:45 PM | 10 Comments
  • Thu, Mar. 24, 8:46 AM
    • Recro Pharma (REPH) FY15 results: Revenues: $52M; R&D Expense: $12.3M (+55.7%); SG&A: $13M (+225.0%); Operating Loss: ($7M) (+41.2%); Net Income: $3M (+117.2%); EPS: $0.21 (+107.5%); Quick Assets: $19.8M (+0.5%).
    • No guidance given.
    | Thu, Mar. 24, 8:46 AM
  • Thu, Mar. 24, 8:29 AM
    | Thu, Mar. 24, 8:29 AM | 1 Comment
  • Tue, Feb. 16, 12:40 PM
    • Recro Pharma (REPH +1%) appoints Fred Graff as Chief Commercial Officer. Previously, he was a strategic consultant. His background includes stints at Sepracor Pharmaceuticals, Vanda Pharmaceuticals and Rhone Poulenc Rorer.
    | Tue, Feb. 16, 12:40 PM
  • Mon, Feb. 1, 11:13 AM
    • Dosing is underway in Recro Pharma's (REPH -0.9%) second Phase 3 clinical trial assessing IV meloxicam for the treatment of acute pain following bunionectomy surgery.
    • The double-blind, placebo-controlled study will randomize ~200 patients to receive either 30 mg of IV meloxicam or placebo once every 24 hours for up to three days following surgery. The primary efficacy endpoint is the summed pain intensity difference over the first 48 hours versus placebo. Top-line data are expected by year-end.
    • A Phase 2 study showed statistically significant reductions in pain intensity in patients receiving IV meloxicam.
    • Meloxicam is an anti-inflammatory and analgesic agent called a COX-2 inhibitor. It has been marketed since the 1990s in an oral formulation by Boehringer Engelheim. Recro acquired the rights to the intravenous/intramuscular formulation from Alkermes in April 2015. Bunionectomy surgery is a very painful procedure that requires an incision in the top or side of the big toe joint.
    • Previously: Recro Pharma's IV meloxicam successful in mid-stage study (Jan. 6)
    | Mon, Feb. 1, 11:13 AM
  • Wed, Jan. 6, 10:52 AM
    • Results from a Phase 2 clinical trial assessing one of Recro Pharma's (REPH +0.5%) lead product candidates, intravenous (IV) meloxicam, for the treatment of acute pain following bunionectomy surgery showed it to be both safe and effective.
    • The primary efficacy endpoint was the difference in pain intensity over 48 hours after surgery versus placebo as measured by a rating scale called Summed Pain Intensity Difference (SPID48). Both the 30 mg dose of IV meloxicam and the 60 mg dose showed statistically significant reductions in post-surgery pain compared to placebo (p=0.007 and p=0.0027, respectively).
    • IV meloxicam was well tolerated with no serious adverse events, bleeding events or injection site reactions observed. The most common adverse events were nausea, headache, dizziness, itchy skin and vomiting. There were no treatment discontinuations due to adverse events.
    • Meloxicam is an anti-inflammatory and analgesic agent called a COX-2 inhibitor. It has been marketed since the 1990s in an oral formulation by Boehringer Engelheim. Recro acquired the rights to the intravenous/intramuscular formulation from Alkermes in April 2015. A Phase 3 study should commence this quarter.
    • Bunionectomy surgery is a very painful procedure that requires an incision in the top or side of the big toe joint.
    • Previously: Recro Pharma completes acquisition of certain Alkermes assets; Shares rise (April 13, 2015)
    | Wed, Jan. 6, 10:52 AM
  • Nov. 13, 2015, 10:31 AM
    • Recro Pharma (REPH -4.2%) Q3 results: Revenues: $16.5M; R&D Expense: $2.7M (-25.0%); SG&A: $3.5M (+218.2%); Operating Loss: ($0.2M) (+95.7%); Net Loss: ($2.2M) (+53.2%); Loss Per Share: ($0.24) (+60.7%); Quick Assets: $28.3M (+43.7%).
    • No guidance given.
    | Nov. 13, 2015, 10:31 AM | 1 Comment
  • Nov. 13, 2015, 7:03 AM
    • Recro Pharma (NASDAQ:REPH): Q3 EPS of -$0.24 misses by $0.04.
    • Revenue of $16.54M beats by $1.29M.
    | Nov. 13, 2015, 7:03 AM
  • Oct. 16, 2015, 5:19 PM
    • Recro Pharma (NASDAQ:REPH) discloses CFO Charles Garner's employment was "terminated" on Oct. 12.
    • Corporate controller Donna Nichols will serve as principle financial officer until a new CFO is named.
    | Oct. 16, 2015, 5:19 PM
  • Sep. 4, 2015, 2:36 PM
    • BioPharmX (BPMX -0.7%) initiated with a Buy rating and $3.50 (133% upside) price target by Sterne Agee CRT.
    • Recro Pharma (REPH +5.3%) initiated with a Buy rating and $19 (30% upside) price target by H.C. Wainwright.
    • AcelRx Pharmaceuticals (ACRX +4.1%) initiated with a Buy rating and $8.50 (101% upside) price target by H.C. Wainwright.
    • NephroGenex (NRX -0.8%) initiated with a Buy rating and $9 (127% upside) price target by H.C. Wainwright.
    • Puma Biotechnology (PBYI -2%) initiated with an Overweight rating and $122 (36% upside) price target by JP Morgan.
    • Teledoc (TDOC -7.4%) initiated with an Outperform rating and $35 (68% upside) price target by Leerink Partners.
    • Aimmune Therapeutics (AIMT -4.1%) initiated with an Outperform rating and $44 (96% upside) price target by Credit Suisse.
    • Endo International (ENDP -2.9%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $85 (18% upside) from $101.
    | Sep. 4, 2015, 2:36 PM | 4 Comments
  • Aug. 14, 2015, 4:10 PM
    • Recro Pharma (NASDAQ:REPH): Q2 EPS of -$0.17 vs. -$0.36 in 2Q14
    • Revenue of $18.66M
    | Aug. 14, 2015, 4:10 PM
  • Jul. 17, 2015, 9:22 AM
    | Jul. 17, 2015, 9:22 AM
  • Jul. 17, 2015, 8:15 AM
    • A Phase 2 clinical trial assessing Recro Pharma's (NASDAQ:REPH) lead product candidate, Dex-IN, for the treatment of acute pain in adult patients undergoing bunionectomy surgery met its primary endpoint significant pain relief over 48 hours compared to placebo.
    • The company intends to meet with the FDA to discuss the results and finalize the parameters of a pivotal Phase 3 trial.
    • Dex-IN, an intranasal formulation of the sedative dexmedetomidine, is being evaluated for the non-opioid treatment of acute post-operative pain following bunionectomy (bunion removal) surgery, a very painful procedure which requires an incision in the top or side of the big toe joint.
    • Shares are up 13% premarket on increased volume.
    | Jul. 17, 2015, 8:15 AM
  • Jul. 8, 2015, 4:31 PM
    • Recro Pharma (NASDAQ:REPH) sells 1,379,311 shares of common stock at $11.60 per share in a private placement with institutional investors generating $16M in gross proceeds.
    • Net proceeds will fund the clinical development of the company's lead product candidates, IV/IM meloxicam and Dex-IN, and general corporate purposes.
    • Today's close was $13.37.
    | Jul. 8, 2015, 4:31 PM
Company Description
Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company that is developing non-opioid therapeutics for the treatment of pain, initially in the postoperativesetting. It offers drug solutions for cancer, musculoskeletal disorders and peripheral neuropathy, cancer breakthrough and... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States